Group 1 - The company announced a share repurchase plan approved on November 11, 2025, aiming to buy back shares worth 100 to 200 million yuan for employee stock ownership plans or equity incentives, with a maximum price of 244 yuan per share, valid until November 11, 2026 [1] - As of January 31, 2026, the company has repurchased a total of 904,054 shares, accounting for 0.98% of the total share capital, with total funds paid amounting to 149,955,134.73 yuan, and the repurchase price range was between 145.59 and 176.79 yuan per share [1]

Summary of Key Points Core Viewpoint - The company, 热景生物 (Hotgen Biotech), has announced a share buyback program, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - As of January 31, 2026, the company has repurchased a total of 904,000 shares, which represents 0.98% of its total share capital [1] - The highest price paid for the repurchased shares was 176.79 yuan per share, while the lowest price was 145.59 yuan per share [1] - The total amount spent on the share buyback was 150 million yuan, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company, Hotgen Biotech (688068.SH), announced a share buyback program, having repurchased a total of 904,000 shares, which represents 0.98% of its total share capital [1] - The highest price paid for the repurchased shares was 176.79 yuan per share, while the lowest price was 145.59 yuan per share [1] - The total amount spent on the share buyback was 150 million yuan, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - On February 2, 2023, Hotgen Biotech experienced a decline of 5.36% with a trading volume of 211 million yuan. The financing data indicated a net buying of 1.17 million yuan for the day, with a total financing and margin balance of 156 million yuan [1] - The financing balance of Hotgen Biotech was reported at 154 million yuan, accounting for 1.21% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low position [1] - In terms of securities lending, Hotgen Biotech had a securities lending balance of 2.27 million yuan, which is above the 90th percentile level over the past year, indicating a high position [1] Group 2 - As of September 30, 2023, Hotgen Biotech had 7,833 shareholders, an increase of 12.9% from the previous period. The average circulating shares per person decreased by 11.43% to 11,835 shares [2] - For the period from January to September 2023, Hotgen Biotech reported a revenue of 310 million yuan, a year-on-year decrease of 19.8%. The net profit attributable to the parent company was -109 million yuan, a significant decrease of 168.12% [2] - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.34 million yuan distributed over the past three years [3]

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

1月27日，热景生物涨5.05%，截至发稿，报154.89元/股，成交2.70亿元，换手率1.92%，总市值143.60 亿元。 资料显示，北京热景生物技术股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业基地庆 丰西路55号院7号楼1-5层，成立日期2005年6月23日，上市日期2019年9月30日，公司主营业务涉及研 发、生产和销售体外诊断试剂及仪器。主营业务收入构成为：检测试剂70.87%，检测仪器19.79%，其 他8.17%，生物原料1.17%。 截至发稿，农冰立累计任职时间7年222天，现任基金资产总规模126.84亿元，任职期间最佳基金回报 174.01%， 任职期间最差基金回报-1.57%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.c ...

据Wind统计，截至1月26日，沪深两市共有133只个股连续5日或5日以上获主力资金净买入。连续获主 力资金净买入天数最多的股票是陕西煤业、伊利股份，均已连续14个交易日获净买入；连续获主力资金 净买入天数较多的还有中金公司、寒武纪-U、联影医疗、热景生物、无锡银行、海天味业、联诚精 密、红塔证券等股。 （文章来源：证券时报网） ...

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

近日，热景生物发布公告称，预计2025年年度实现营业收入4亿元至4.2亿元，与上年同期相比，同比减少17.79%至 21.71%。 此外，其他联营企业在生物创新药领域的研发投入也导致投资损失扩大，进一步影响了公司净利润。 （热景生物公告） 预计归母净利润约亏损2.1亿元至2.3亿元，与上年同期相比，亏损增加9.94%至20.42%。此外，预计归母净利润扣除非 经常性损益后约亏损2.5亿元至2.7亿元。 公告中提到，业绩下滑的主要原因包括行业政策影响导致价格下降及需求减少，以及税收政策调整对综合毛利率的影 响。同时，公司对联营企业舜景医药增资，使其成为控股子公司，研发费用大幅增加，对净利润产生较大影响。 ...

Core Viewpoint - The company, 热景生物, is forecasting a significant decline in its 2025 financial performance, with expected revenues between 400 million to 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71%, and a net loss projected between 210 million to 230 million yuan, which is an increase from the previous year's loss of 191 million yuan [2] Financial Performance - The company's revenue peaked at 3.556 billion yuan in 2022, with a profit of 944 million yuan, but has since faced two consecutive years of losses [3] - In 2024, the company reported revenues of 511 million yuan and a net loss of 191 million yuan, with a non-recurring net loss of 231 million yuan [3] - By the third quarter of 2025, revenues were 310 million yuan, a year-on-year decline of 19.8%, with a net loss of 109 million yuan [3] Industry Challenges - The in vitro diagnostic industry is facing significant challenges due to policy changes, particularly centralized procurement, which has impacted product pricing and increased competition [3][4] - The company's main business, in vitro diagnostic reagents and instruments, accounts for 99% of its revenue, and the pricing pressure has led to a decline in both single-machine revenue and output rates [3] Revenue Dynamics - In 2024, excluding non-conventional testing, the company's revenue grew by 23.10%, but reagent business revenue fell by 18.55%, with growth primarily driven by instrument sales, which saw a 262.79% increase in volume and a 289.79% increase in revenue [3] - The gross margin for instruments improved from -11.20% to 6.41% due to adjustments in sales strategy [3] Strategic Adjustments - The company shifted its sales strategy in the second half of 2023 to a model that combines sales and deployment, responding to increased demand from hospitals [4] - However, this strategy has led to a lag in reagent sales growth, which increased by only 8.24% compared to a 13.21% growth in instrument sales [4] Investment in Innovation - In response to stagnant growth in its core business, the company has invested in innovative pharmaceuticals, including stakes in 舜景医药, 尧景基因, and 智源生物, but these investments have not yet generated revenue and have resulted in significant losses [5] - The company reported an investment loss of 47.63 million yuan in 2024 and has increased its stake in 舜景医药, which is now a subsidiary [5] - 舜景医药 is developing SGC001, a novel treatment for acute myocardial infarction, which has received clinical trial approval but is still in the early stages of development [5]